Press Releases

Date Title and Summary Additional Formats
Toggle Summary Minerva Neurosciences Completes Private Placement, Raises $31 Million View HTML
Toggle Summary Minerva Neurosciences Announces $31 Million Financing View HTML
Toggle Summary Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia View HTML
Toggle Summary Minerva Neurosciences Announces $15 Million Debt Facility With Oxford Finance LLC and Silicon Valley Bank
Funding supports Minerva continuing to advance the clinical program for MIN-101, the company's investigational compound in development for treatment of schizophrenia
View HTML
Toggle Summary Minerva Neurosciences Reports Positive Data Showing an Analog of Minerva's MIN-301 Compound Improves Symptoms of Parkinson's Disease in Primates View HTML
Toggle Summary Minerva Neurosciences Announces Completion of Development and Final Selection of Once-Daily Dose Formulation of MIN-101 for Its Schizophrenia Program
New Formulation to be Used in Planned Phase 2b Clinical Trial Has Been Developed to Offer Improved Safety, Tolerability and Pharmacokinetic Profile
View HTML
Toggle Summary Minerva Neurosciences Appoints Dr. Remy Luthringer as CEO View HTML
Toggle Summary Dr. Remy Luthringer, Minerva President and Chief Scientific Officer, to Present at CNS Summit View HTML
Toggle Summary Minerva Neurosciences Reports Third Quarter 2014 Financial Results View HTML
Toggle Summary Minerva Neurosciences to Host Third Quarter 2014 Financial Results Webcast and Conference Call View HTML